Lipocine Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:LPCN) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 20.5 M18.58 M16.07 M17.01 M25.36 M23.84 M Total liabilities 1.3 M1.45 M1.93 M2.53 M2.53 M2.07 M Total equity 19.2 M17.13 M14.14 M14.48 M22.83 M21.77 M Total liabilities & shareholders' equities 20.5 M18.58 M16.07 M17.01 M25.36 M23.84 M Total debt —————— Net debt ——————

News

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.13%

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates

Lipocine completes patient visits in phase 3 trial for PPD treatment

H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress

Lipocine completes enrollment in phase 3 trial for PPD treatment

Lipocine’s PPD drug trial continues after positive safety review

Lipocine reaches 80% enrollment in postpartum depression drug trial

Lipocine presents LPCN 2101 epilepsy candidate data at annual AES meeting

Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline